ArticleEClinicalMedicine2023

Multicenter phase I dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma.

Sheng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.